Immune Pharmaceuticals, Inc.

149 articles about Immune Pharmaceuticals, Inc.

• Immune Pharma Signs Agreement To Regain Worldwide Rights For Ceplene

  6/15/2017

• Immune Pharma Receives Nasdaq Letters

  5/30/2017

• Immune Pharma Announces Private Placement Of Up To $3.4 Million

  5/4/2017

• Immune Pharma Receives Nasdaq Letter

  4/24/2017

• Immune Pharma CEO Steps Down to Lead R&D in Restructuring, May Spin Off Oncology Unit

  4/24/2017

• Immune Pharma Signs Letter Of Intent With Pint Pharma Regarding License And Commercializion Of Ceplene In Latin America

  4/20/2017

• Immune Pharma Announces 1-for-20 Reverse Stock Split

  4/12/2017

• Immune Pharma Granted Additional Time To Comply With Nasdaq Listing Requirement

  3/13/2017

• Immune Pharma Reports Encouraging Preliminary Data With Bertilimumab In An Open Label Phase II Study In The Rare Dermatological Auto-Immune Disease, Bullous Pemphigoid

  2/28/2017

• Immune Pharma Announces The Launch Of REMAIN, An International Overall Survival Study With Ceplene And Low Dose Proleukin In Remission Maintenance In Acute Myeloid Leukemia

  2/17/2017

• Immune Pharma Appoints New Chairman Of The Board Of Directors

  1/27/2017

• Immune Pharma Enters A Research Partnership To Develop Mono- And Bispecific Antibodies Against Novel Targets In The Tumor Microenvironment

  1/23/2017

• Immune Pharma Release: Company Will Request An Appeal To Regain Compliance With Nasdaq's Minimum Bid Price Rule

  1/10/2017

• Immune Pharma Announces Immuno-Oncology R&D Update On December 8, 2016

  11/22/2016

• Immune Pharma Secures Up To $11 Million In New Financing To Be Deployed With A Focus On Bertilimumab Clinical Development

  11/17/2016

• Immune Pharma Receives FDA Guidance For Low Dose IL-2 In Combination With Phase III Pivotal Trial Of Its AML Therapy Ceplene

  10/27/2016

• Immune Pharma Announces Formation Of Management Team For Maxim Pharmaceuticals, Inc., Its Pain And Neurology Subsidiary

  10/17/2016

• Immune Pharma Signs Agreement To Fund Maxim Pharmaceuticals, Inc., Its Pain And Neurology Subsidiary

  9/16/2016

• Immune Pharma Receives $2 Million Investment In Common Stock At $0.50 Per Share

  9/7/2016

• Immune Pharma Provides Business And R&D Update And Announces Second Quarter 2016 Financial Results

  8/16/2016